Connect with us

Health & Wellness

Benefits of LDN (Low dose naltrexone)

Published

on

Just over sixty years ago, in 1960, the average lifespan for an adult in the United States was 69.7 years old. By 2015 this increased by almost ten years and continued to climb each year. 

Projections published by the United States Census Bureau believed that by 2060, life expectancy will reach an all-time high of 85.6 years.     

Though there are many factors that contribute, like better safety measures and precautions, the significant increase is primarily attributed to a reduction in viral infections, diseases, and cardiovascular mortality and increased health prevention programs.     

Thanks to modern science and medicine, there are excellent drugs that allow people to delay aging and the diseases that come along with it. A great example is the drug LDN. Low dose naltrexone, commonly known as LDN, can prevent these diseases entirely or prolong an individual’s disease-free years. It is considered a longevity therapy with incredible health benefits.  

The drug has been prescribed for over 40 years with an outstanding safety record. In 1985 it was used to treat autoimmune diseases and viral infections. LDN is an oral medicine commonly delivered at a higher dose to control cravings for opioids and alcohol and is considered a low dose when the dosage is less than 10mg.   

LDN has a long list of longevity benefits primarily because of its effect on endorphin levels. Endorphins are polypeptides that are involved in serotonin and dopamine production. With a higher level of endorphins, you will feel good, but when levels are low, it can cause health issues like depression, cognitive degeneration, and fibromyalgia. Individuals with these diseases are low in Opioid Growth Factor (OGF).    

LDN increases OGF by binding opioid receptors, displacing the body’s naturally produced OGF. This makes the cells OGF-deficient, which triggers a few different processes. The first is an increase in receptor production, which captures more OGF. The second is an increase in receptor sensitivity that captures OGF, and the third is increasing the output of OGF.   

When a person takes LDN, the receptors are only blocked for a few hours. This creates a rebound effect, boosting endorphin levels even higher. This results in several benefits including:  

A reduction in cancer risk

LDN has been found to reduce the risk of cancer. One report found that LDN affected tumors including non-small cell lung cancer at the cellular level through augmentation of the immune system. Additionally, a mouse study published in Science Direct found that LDN inhibited colorectal cancer progression and promoted apoptosis.

A reduction chronic pain

There is strong clinical evidence that LDN reduces chronic pain. For example, LDN can be effective in reducing the symptoms of fibromyalgia. Fibromyalgia is a condition that causes pain all over the body. One cohort study found that low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a reduction greater than 30% compared to the placebo. 

Additionally, a randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessed daily pain levels and found that it significantly reduced baseline pain.

A reduction in inflammation

Inflammation can cause severe and life-threatening health conditions. With LDN, inflammation and its potential threats can be reduced. This is seen with the lowering of ESR (erythrocyte sedimentation rate), a marker of inflammation in the body.

In a 10-week crossover trial published in Biomedicines, it was discovered that LDN was associated with a reduction in plasma concentrations of pro-inflammatory interleukin cytokines, as well as transforming growth factor, tumor necrosis factor, and granulocyte-colony stimulating factor.

An improvement in mood

As mentioned previously, LDN can increase endorphins. Endorphins trigger positive feelings in the body, making you feel happier and energized. Because of this, one of the benefits of LDN is improved overall mood and sense of well-being.

Weight loss

Another benefit of LDN is weight loss. A study published in Experimental and Clinical Endocrinology & Diabetes looked at LDN use with hyperandrogenic women. The results of the study found that naltrexone use helped lower fasting insulin levels by up to 40%. Additionally, a study of obese women found that naltrexone could help increase growth hormone levels which can increase lean body mass development and the ability to burn fat. Lastly, a third study found that when combined with Bupropion, it was more effective for weight loss than taking Bupropion alone.

In addition to these incredible benefits, LDN has been found to reduce brain fog and fatigue,

modulate the immune system and reduce the chance of autoimmunity. 

These benefits result from the impact LDN has on a cellular level. When taken, you can experience several or all of these benefits, improving longevity and delaying aging. To receive these benefits, you will need a prescription for the drug. This can be accessed through a pharmacy specializing in longevity therapies where you will also receive a personalized consultation to determine the proper dosage. 

For example, with the telehealth subscription service AgelessRx.com you can visit their website to register for a free medical evaluation. Following this, you can purchase a one-month or three-month subscription. Generally, a 4.5mg dose will be prescribed, although the doctor may recommend a different dose during the medical intake process. 

You should take LDN daily at bedtime between 9 pm and 2 am to achieve the benefits listed here. When you start taking it, you will begin at a lower dose of about 1.5mg and gradually work your way up to about 4.5mg. There are both short-term and long-term benefits you will experience. The long-term benefits are the prevention of diseases, and short-term benefits include a reduction in symptoms related to inflammation such as back pain, fatigue, weight gain, and joint pain. 

LDN is incredibly safe, but you could experience some mild to moderate side effects when you start taking it. These side effects typically diminish with five days and can be reduced by starting with a low dose. 

If the projections are correct, you may live a longer, healthier, and happier life than your parents and grandparents. LDN is proof of the incredible medical advancements that can improve the length and quality of life.

Continue Reading
Comments

Health & Wellness

UN-backed COVAX mechanism delivers its 1 billionth COVID-19 vaccine dose

Published

on

photo © UNICEF/Aimable Twiringiyima

With a 1.1 million jab delivery in Rwanda this weekend, the World Health Organization’s multilateral initiative to provide equal access to vaccines for all reached the one billion milestone.

Along with the Coalition for Epidemic Preparedness Innovations (CEPI), the Vaccine Alliance GAVI, and partners, WHO has led the largest vaccine procurement and supply operation in history with deliveries to 144 countries to date.

According to a press release published on Sunday, as of 13 January 2022, out of 194 countries members of WHO, 36 have vaccinated less than 10% of their population, and 88 less than 40%.

COVAX’s ambition was compromised by hoarding/stockpiling in rich countries, catastrophic outbreaks leading to borders and supply being locked. And a lack of sharing of licenses, technology, and know-how by pharmaceutical companies meant manufacturing capacity went unused”, the agency explained.

On 24 February 2021, Ghana became the first country in the world to receive vaccines through COVAX when 600,000 doses of the Oxford–AstraZeneca vaccine were delivered to Accra. 

The work that remains

COVAX is currently working with governments, manufacturers and partners to ensure that when countries receive vaccines, they can get them to people quickly.

“The work that has gone into this (1 billion) milestone is only a reminder of the work that remains”, the UN’s health agency underscored.

They added that with updated vaccines in the pipeline, citizens should demand that governments and pharmaceutical companies share health tools globally and “bring an end to the death and destruction cycles of this pandemic, limit new variants and drive a global economic recovery”.

COVAX is one of three pillars of the Access to COVID-19 Tools (ACT) Accelerator, which was launched by WHO in April 2020 in response to the pandemic.

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. 

Continue Reading

Health & Wellness

WHO recommends two new drugs to treat patients with COVID-19 

Published

on

Around two million doses of Sotrovimab are being produced globally in the first half of 2022. © GlaxoSmithKline

The World Health Organization (WHO) on Thursday reccommended two new drugs to treat patients with COVID-19, one for patients with critical disease, and another deemed effective for non-severe cases.

The first drug, baricitinib, is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis.

According to the WHO Guideline Development Group, it is “strongly recommended” for patients with severe or critical disease in combination with corticosteroids.

The group of international experts based their recommendation on “moderate certainty evidence” that it improves survival and reduces the need for ventilation.

There was no observed increase in adverse effects.

The experts note that it has a similar effectas other arthritis drugs called interleukin-6 (IL-6) inhibitors. Because of that, when both drugs are available, they suggest choosing the best option based on cost, availability, and clinician experience.

It is not recommended to use both drugs at the same time.

The experts also advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical cases of COVID-19 infection.

According to them, trials undergone using these drugs failed to show any benefits arising using either drug,and suggested a possible increase in serious side effects with tofacitinib.

Non-severe cases

In the same update, WHO makes a conditional recommendation for the use of a monoclonal antibody known as sotrovimab in patients with non-severe cases.

According to them, the drug should only be administered to patients at the highest risk of hospitalisation. In those at lower risk, it onlyshowed “trivial benefits”. 

A similar recommendation has been madepreviously, for another monoclonal antibody drug, casirivimab-imdevimab, and the experts say there is insufficient data to recommend one over the other.

For both, the effectiveness against new variants, like Omicron, is still uncertain. 

The group will update their guidelines for monoclonal antibodies when more data becomes available.

Recommendations

These recommendations are based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical infections.

Developed by WHO with the methodological support of MAGIC Evidence Ecosystem Foundation, the guidelinesprovide trustworthy guidance and help doctors make better decisions with their patients.

According to the agency, the guidelines are useful in fast moving research areas, because they allow researchers to update evidence summaries as new information becomes available.

The latest guidance also updates recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical COVID-19; conditional recommendations for the use of casirivimab-imdevimab (another monoclonal antibody treatment) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine, regardless of disease severity.

Continue Reading

Health & Wellness

Omicron fuels record weekly COVID-19 cases, but deaths ‘stable’

Published

on

Fuelled by Omicron, more than 15 million new cases of COVID-19 were reported around the world last week, by far the most cases reported in a single seven day period, the World Health Organization (WHO) informed on Wednesday. 

Briefing reporters in Geneva, the UN health agency chief, Tedros Adhanom Ghebreyesus, said the “huge spike” is being driven by the Omicron variant, which is rapidly replacing Delta in almost all countries. 

Despite the number of cases, the weekly reported deaths have “remained stable” since October last year, Tedros added, at an average of 48,000. The number of patients being hospitalized is also increasing in most countries, but it is not at the level seen in previous waves.

He told reporters this is possibly due to the reduced severity of Omicron, and widespread immunity from vaccination or previous infection.

‘50 thousand deaths too many’

For the WHO chief, while Omicron causes less severe disease than Delta, it remains a dangerous virus, particularly for those who are unvaccinated.

Almost 50 thousand deaths a week is 50 thousand deaths too many”, Tedros said. “Learning to live with this virus does not mean we can, or should, accept this number of deaths.”

For him, the world cannot “allow this virus a free ride” when so many people around the world remain unvaccinated.

In Africa, for example, more than 85 per cent of people are yet to receive a single dose of vaccine.

“We cannot end the acute phase of the pandemic unless we close this gap”, he said. 

Making progress

Tedros then listed some progress towards reaching the target of vaccinating 70 per cent of the population of every country by the middle of this year. 

In December, COVAX shipped more than double the number of doses it distributed in November. In the coming days, the initiative should ship its one billionth vaccine dose. 

Some of the supply constraints from last year are also starting to ease, Tedros said, but there’s still have a long way to go. 

So far, 90 countries have still not reached the 40 per cent target, and 36 of those countries have vaccinated less than 10 per cent of their populations.

New vaccines

Tedros also highlighted an interim statement from the WHO Technical Advisory Group on COVID-19 Vaccine Composition, released on Tuesday, stressing that further vaccines are needed that have a greater impact on preventing infection. 

Until such vaccines are developed, the experts explained, the composition of current vaccines may need to be updated. 

The Group also said that a vaccination strategy based on repeated booster doses is “unlikely to be sustainable.”

A heavy toll

According to Tedros, the overwhelming majority of people admitted to hospitals around the world are unvaccinated.

At the same time, while the immunizations remain very effective at preventing severe disease and death, they do not fully prevent transmission.

“More transmission means more hospitalizations, more deaths, more people off work, including teachers and health workers, and more risk of another variant emerging that is even more transmissible and more deadly than Omicron”, Tedros explained. 

The sheer number of cases also means more pressure on already overburdened and exhausted health workers.

A study published last year showed that more than one in four health workers have experienced mental health issues during the pandemic. Data from several countries also show that many have considered leaving or have left their jobs.

Pregnant women

On Tuesday, WHO hosted a global webinar, attended by clinicians from around the world, on the clinical management of the virus during pregnancy, childbirth and the early postnatal period. 

As stated earlier in the pandemic, pregnant women are not at higher risk of contracting COVID-19, but if they are infected, they are at higher risk for severe disease.

That’s why it’s vital that pregnant women in all countries have access to vaccines to protect their own lives, and those of their babies”, Tedros said. 

The agency chief also called for pregnant women to be included in clinical trials for new treatments and vaccines. 

He also stressed that, fortunately, mother to baby transmission in utero or during birth is very rare, and no active virus has been identified in breast milk. 

Continue Reading

Publications

Latest

Trending